Evidence map›Paper›PMID 41084861›Full record

ArticleFuture microbiology2025

Recombinant

Yutong Li, Xianxian Wei, Yijie Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yutong LiXinjiang Key Laboratory of Biological Resources and, Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, P.R. China.
Xianxian WeiXinjiang Key Laboratory of Biological Resources and, Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, P.R. China.
Yijie LiXinjiang Key Laboratory of Biological Resources and, Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsAnti-tumor vaccines that target the early proteins E6 and E7 of human papillomavirus (HPV) type 16 represent a potential immunotherapy for cervical cancer, although underlying mechanisms remain unclear. Lactococcus lactis (

methodsStudy performed flow cytometry and MTT to analyze the adjuvant efficacy in promoting DC activation and proliferative capacity of T lymphocytes. The anti-tumor effect of DC vaccine prepared with

resultsRecombinant

conclusionsThis study demonstrated that recombinant

Indexed as

Cancer VaccinesDendritic CellsHuman papillomavirus 16Lactococcus lactisOncogene Proteins, ViralPapillomavirus E7 ProteinsPapillomavirus VaccinesRepressor ProteinsUterine Cervical NeoplasmsAdjuvants, ImmunologicAnimalsFemaleHumansMiceMice, Inbred C57BLPapillomavirus InfectionsAdjuvants, ImmunologicCancer VaccinesE6 protein, Human papillomavirus type 16oncogene protein E7, Human papillomavirus type 16Oncogene Proteins, ViralPapillomavirus E7 ProteinsPapillomavirus VaccinesRecombinant Fusion ProteinsRepressor ProteinsVaccines, Syntheticantigen presentationcervical cancerDC vaccineHPV16-E6E7 fusion antigenLactococcus lactis

Identifiers

PMID41084861
PMCPMC12645867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.